Longevity Health Holdings Inc. (XAGEW) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Longevity Health Holdings Inc. (XAGEW) Healthcare & Pipeline Overview

Longevity Health Holdings Inc. is a Pittsburgh-based biotechnology firm established in 2008, specializing in plasma-based bioactive material (PBM) development. The company's primary focus is on CT-101, a lead product candidate designed to accelerate bone and tissue repair for various medical conditions, including fractures, fusions, and chronic wounds, leveraging its proprietary technology.

What Is the Investment Thesis for XAGEW?

Longevity Health Holdings Inc. presents a research profile centered on its proprietary plasma-based bioactive material (PBM) technology, with CT-101 as its lead product candidate targeting a broad spectrum of regenerative medicine applications. The core value driver lies in CT-101's potential to accelerate bone healing across multiple orthopedic indications, including tibia fractures, foot/ankle fusions, and spinal fusions, alongside its utility as a dental bone graft substitute and bone void filler. Furthermore, its application in tissue healing for androgenetic alopecia and chronic wound care diversifies its market potential. Key growth catalysts include successful progression of CT-101 through clinical development stages, securing regulatory approvals, and potential market adoption across these varied, high-demand therapeutic areas. The company's gross margin of 57.1% suggests potential efficiency in its core operations, despite its current early-stage status. However, the company operates with a significant negative profit margin of -380.7% and a market capitalization of $0.00B, indicating substantial ongoing investment in R&D and a pre-revenue or minimal-revenue phase. The small team of 15 employees underscores a focused, agile development approach, but also highlights the resource intensity of bringing multiple indications to market. Future milestones related to clinical trial data and regulatory submissions will be critical for validating the PBM platform and driving potential value.

Based on FMP financials and quantitative analysis

XAGEW Key Highlights

Market Capitalization: $0.00B, indicating an early-stage or micro-cap company.

• Profit Margin: -380.7%, reflecting significant investment in research and development without substantial revenue generation.
• Gross Margin: 57.1%, suggesting potential efficiency in the core cost of goods sold for its developing technology.
• Beta: 0.37, indicating lower volatility relative to the broader market.
• Employees: 15, highlighting a lean operational structure focused on specialized R&D.

Who Are XAGEW's Competitors?

XAGEW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are XAGEW's Key Strengths?

Proprietary plasma-based bioactive material (PBM) technology.

• Broad potential applications of lead candidate CT-101 across diverse medical fields.
• Focused research and development efforts with a lean employee base.
• Positive gross margin of 57.1%.

What Are XAGEW's Weaknesses?

Early-stage company with a market capitalization of $0.00B.

• Significant negative profit margin of -380.7%, indicating unprofitability.
• Dependence on the successful development and commercialization of a single lead product candidate (CT-101).
• Limited financial resources compared to larger competitors.

What Could Drive XAGEW Stock Higher?

XAGEW catalyst: Announcement of clinical trial initiation or progression for CT-101 in bone healing indications (e.g., tibia fractures, spinal fusions).

• Release of preclinical or early-stage clinical data for CT-101 in tissue healing applications (e.g., androgenetic alopecia, chronic wounds).
• Future regulatory submissions or designations (e.g., Orphan Drug status, Fast Track) for CT-101 in any of its targeted therapeutic areas.
• Continued research and development efforts to optimize and expand the applications of its plasma-based bioactive material platform.

What Are the Key Risks for XAGEW?

Financial-distress signal — its Altman Z-Score of -34.54 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Significant negative profit margin of -380.7% indicating substantial cash burn and reliance on future funding rounds.
• Clinical trial failures or delays for CT-101 across any of its multiple indications, which could impede market entry and future revenue.
• Inability to secure adequate capital and funding necessary to advance CT-101 through costly clinical development and commercialization phases.
• Intense competitive pressure from larger, more established biotechnology and pharmaceutical companies with greater resources.
• Regulatory hurdles and prolonged approval processes for novel regenerative medicine products, delaying market access.

What Are the Growth Opportunities for XAGEW?

• Expansion into Orthopedic Bone Healing Market: Longevity Health Holdings Inc.'s CT-101 is being developed as a bone healing accelerant for significant orthopedic indications, including tibia fractures, foot/ankle fusions, and spinal fusions. The global orthopedic market, particularly for trauma and reconstructive procedures, represents a substantial opportunity, driven by an aging population and increasing incidence of injuries. Successful clinical development and regulatory approval of CT-101 in these areas could position the company to address a critical need for faster and more effective bone repair, potentially reducing patient recovery times and healthcare costs. The broad utility across multiple bone repair scenarios enhances its market penetration potential.
• Penetration of the Dental Bone Graft Market: CT-101's application as a dental bone graft substitute targets a significant segment within the oral and maxillofacial surgery market. Dental bone grafting procedures are common for dental implant placement, periodontal defect repair, and ridge augmentation. The demand for effective and biocompatible bone graft materials is consistently high. By offering a plasma-based bioactive material, Longevity Health Holdings Inc. could provide a differentiated solution that potentially offers superior integration and regeneration compared to existing synthetic or allograft options, capturing a share of this specialized and growing market.
• Addressing Bone Void Filler Needs: The development of CT-101 as a bone void filler positions Longevity Health Holdings Inc. to cater to a wide array of surgical procedures where bone defects need to be filled and regenerated. This includes trauma, tumor resection, and reconstructive surgeries across various anatomical sites. The market for bone void fillers is diverse and substantial, driven by the need for materials that can promote natural bone healing and provide structural support. CT-101's PBM technology could offer advantages in terms of biocompatibility and osteoinductive properties, making it a noteworthy option for surgeons seeking enhanced regenerative outcomes.
• Entry into the Androgenetic Alopecia Treatment Market: Longevity Health Holdings Inc. is developing CT-101 for androgenetic alopecia, a widespread condition affecting millions globally. The hair loss treatment market is large and continuously seeking innovative, effective, and minimally invasive solutions beyond current pharmaceutical and surgical options. If CT-101 can demonstrate efficacy in stimulating hair growth and regeneration through its plasma-based mechanism, it could tap into a significant consumer and medical aesthetic market, offering a novel approach to a condition with high patient demand for new therapies.
• Impact on Chronic Wound Healing: The application of CT-101 as a tissue healing accelerant for chronic wounds represents a critical growth opportunity. Chronic wounds, such as diabetic foot ulcers, venous leg ulcers, and pressure ulcers, pose a substantial burden on healthcare systems and significantly impair patients' quality of life. The market for advanced wound care products is growing due to the increasing prevalence of diabetes and an aging population. A PBM-based solution like CT-101, capable of stimulating tissue repair, could offer a breakthrough in accelerating the closure of difficult-to-heal wounds, thereby addressing a major unmet medical need.

What Are XAGEW's Competitive Advantages?

• Proprietary plasma-based bioactive material (PBM) technology, offering a unique approach to tissue regeneration.
• Broad applicability of the lead product candidate, CT-101, across multiple therapeutic areas (orthopedics, dental, dermatology, wound care).
• Potential for intellectual property protection surrounding its PBM composition and manufacturing processes.
• Focused expertise in developing advanced regenerative solutions for complex medical conditions.

What Does XAGEW Do?

Longevity Health Holdings Inc., established in 2008 and headquartered in Pittsburgh, Pennsylvania, is a biotechnology company dedicated to advancing regenerative medicine through its proprietary plasma-based bioactive material (PBM) technology. The company's core mission revolves around developing innovative solutions to stimulate tissue repair and growth following injury, disease, and the natural processes of aging. From its inception, Longevity Health Holdings Inc. has focused its research and development efforts on harnessing the body's natural healing capabilities. The cornerstone of the company's product pipeline is CT-101, a versatile lead product candidate designed to act as a bone healing accelerant and a tissue healing accelerant. In the orthopedic space, CT-101 is being developed for a range of critical applications, including accelerating the healing of tibia fractures, facilitating foot and ankle fusions, and enhancing spinal fusions. Beyond these major orthopedic indications, CT-101 also holds promise as a dental bone graft substitute, addressing the need for effective bone regeneration in oral and maxillofacial procedures, and as a general bone void filler for various skeletal defects. Expanding its therapeutic reach, Longevity Health Holdings Inc. is also exploring CT-101's potential in tissue regeneration outside of bone. Specifically, the company is developing CT-101 for the treatment of androgenetic alopecia, a common form of hair loss, aiming to stimulate hair follicle regeneration. Furthermore, CT-101 is under investigation for its efficacy in chronic wound healing, an area with significant unmet medical needs where traditional treatments often fall short. With a lean team of 15 employees, Longevity Health Holdings Inc. maintains a focused approach on bringing its PBM technology, particularly CT-101, through development stages to address multiple high-impact medical conditions. The company's strategy emphasizes leveraging its unique material science to penetrate diverse healthcare markets, positioning itself as an innovator in regenerative therapies.

What Products and Services Does XAGEW Offer?

• Develops proprietary plasma-based bioactive material (PBM) technology.
• Focuses on stimulating tissue repair and growth after injury, disease, and aging.
• Its lead product candidate is CT-101, a versatile PBM.
• CT-101 is designed as a bone healing accelerant for tibia fractures, foot/ankle fusion, and spinal fusion.
• CT-101 is also being developed as a dental bone graft substitute and bone void filler.
• CT-101 is being explored as a tissue healing accelerant for androgenetic alopecia (hair loss).
• CT-101 also targets the treatment of chronic wound healing.

How Does XAGEW Make Money?

• Currently focused on research and development of its lead product candidate, CT-101.
• Future revenue generation is anticipated through the commercialization and sales of CT-101 across various medical indications.
• Potential for licensing agreements with larger pharmaceutical or medical device companies for its PBM technology.
• Aims to generate revenue from product sales in orthopedic, dental, dermatological, and wound care markets upon regulatory approval.

What Industry Does XAGEW Operate In?

Longevity Health Holdings Inc. operates within the dynamic and rapidly evolving biotechnology sector, specifically targeting the regenerative medicine and biomaterials industry segments. This sector is characterized by intense research and development efforts aimed at developing novel therapies to repair, replace, or regenerate damaged tissues and organs. Key market trends include an increasing aging population, a rising incidence of chronic diseases, and growing demand for advanced wound care solutions and orthopedic repair technologies. Longevity Health Holdings Inc. positions itself as an innovator by focusing on plasma-based bioactive materials (PBM), offering a distinct approach compared to traditional synthetic grafts, growth factors, or cell-based therapies. The competitive landscape includes established pharmaceutical companies, larger biotechnology firms, and numerous smaller startups, all vying for market share in areas like orthopedics, dermatology, and wound care. Longevity Health Holdings Inc.'s strategy is to leverage the broad applicability of its lead candidate, CT-101, to carve out a niche across multiple therapeutic areas, differentiating itself through its specific PBM technology.

Who Are XAGEW's Key Customers?

• Orthopedic surgeons and clinics treating bone fractures, fusions, and defects.
• Dental professionals and oral surgeons requiring bone graft substitutes.
• Dermatologists and hair restoration clinics addressing androgenetic alopecia.
• Wound care specialists and hospitals managing chronic wounds.
• Patients suffering from bone injuries, hair loss, and difficult-to-heal wounds.

Company Profile

Longevity Health Holdings Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Pittsburgh, US. The company is led by CEO Janakiram Ajjarapu. XAGEW has traded publicly since 2025.

Return on equity for Longevity Health Holdings Inc. stands at 107.4%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.07 means current liabilities exceed short-term assets, a liquidity point worth watching.

XAGEW Valuation & Market Position

Relative to its peer group, XAGEW's quantitative score of 54/100 is below the peer average of 76/100.

Quarterly Financial Performance: Longevity Health Holdings Inc.

Revenue for Longevity Health Holdings Inc. came in at $392K during Q1 2026, a 17.2% contraction versus the preceding quarter. The company recorded a net loss of $1.4M, with diluted EPS of $-0.75. Quarter-over-quarter revenue has been mixed, typical for a unknown company operating in Healthcare. Across the four most recent quarters, XAGEW averaged $-0.72 in diluted EPS.

Longevity Health Holdings Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -34.54 places it in the distress zone, a signal of elevated financial risk.

XAGEW Financials

XAGEW Latest News

No recent news available for XAGEW.

XAGEW Analyst Consensus

XAGEW MoonshotScore

Common Questions About XAGEW (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources